Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis.

CONCLUSIONS: In this systematic review and meta-analysis, we did not observe higher rate of BCR after TRT for nonmetastatic CaP patients after definitive local therapy. Based on these data, others and we have outlined a phase I/II trial assessing the safety and benefits of TRT in select men with secondary symptomatic hypogonadism who have no active disease after definitive local CaP therapy with curative intent. PMID: 31296421 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31296421?dopt=Abstract

Source: Urologic Oncology - July 7, 2019 Category: Urology & Nephrology Authors: Kardoust Parizi M, Abufaraj M, Fajkovic H, Kimura S, Iwata T, D'Andrea D, Karakiewicz PI, Shariat SF Tags: Urol Oncol Source Type: research